HRP20020625A2 - Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses - Google Patents
Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses Download PDFInfo
- Publication number
- HRP20020625A2 HRP20020625A2 HR20020625A HRP20020625A HRP20020625A2 HR P20020625 A2 HRP20020625 A2 HR P20020625A2 HR 20020625 A HR20020625 A HR 20020625A HR P20020625 A HRP20020625 A HR P20020625A HR P20020625 A2 HRP20020625 A2 HR P20020625A2
- Authority
- HR
- Croatia
- Prior art keywords
- aryl
- alkoxy
- alkyl
- substituted
- halogen
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 2
- -1 amino, hydroxy, thio Chemical group 0.000 claims description 114
- 125000003545 alkoxy group Chemical group 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 74
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 46
- 229910052736 halogen Inorganic materials 0.000 claims description 40
- 150000002367 halogens Chemical class 0.000 claims description 40
- 125000003282 alkyl amino group Chemical group 0.000 claims description 37
- 125000004414 alkyl thio group Chemical group 0.000 claims description 35
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 34
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000003367 polycyclic group Chemical group 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010059245 Angiopathy Diseases 0.000 claims description 3
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 4
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XYDLIZKNTRKHRO-UHFFFAOYSA-N 2-n,2-n,6-n,6-n,4-pentamethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine;hydrochloride Chemical compound Cl.CC1N=C(N(C)C)NC(N(C)C)=N1 XYDLIZKNTRKHRO-UHFFFAOYSA-N 0.000 description 1
- JLQGYOOFSXGDOL-UHFFFAOYSA-N 4-ethyl-6-n,6-n-dimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine;hydrochloride Chemical compound Cl.CCC1N=C(N)NC(N(C)C)=N1 JLQGYOOFSXGDOL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000002345 steroid group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Sadašnji izum se odnosi na amino derivate dihidro-1,3,5-triazina koji se upotrebljavaju za liječenje bolesti povezanih sa sindromom rezistencije na inzulin.
Amino derivati dihidro-1,3,5-triazina imaju hipoglikemijska svojstva koja su opisana u JP-A-73 64 088 i JP-A-79 14 986.
Ovaj izum otkriva nove spojeve koji imaju poboljšana svojstva.
Predmet ovog izuma je spoj opće formule (I):
[image]
u kojoj:
R1, R2, R3 i R4 su nezavisno odabrani od sljedećih skupina:
- H,
- alkil (C1-C20), supstituiran ili ne, s halogenom, alkil (C1-C5), alkoksi (C1-C5), cikloalkil (C3-C8),
- alkilen (C2-C20), supstituiran ili ne, s halogenom, alkil (C1-C5), alkoksi (C1-C5),
- alkin (C2-C20), supstituiran ili ne, s halogenom, alkil (C1-C5), alkoksi (C1-C5),
- cikloalkil (C3-C8), supstituiran ili ne, s alkil (C1-C5), alkoksi (C1-C5),
- heterocikloalkil (C3-C8), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s alkil (C1-C5), alkoksi (C1-C5),
- aril (C6-C14) alkil (C1-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- aril (C6-C14), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- heteroaril (C1-C13), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
R1 i R2 iz jednog dijela i R3 i R4 iz drugog dijela mogu s atomom dušika formirati prsten od n članova (n je između 3 i 8), koji sadrži ili ne sadrži jedan ili više heteroatoma odabranih od N, O, S, i može biti supstituiran s jednom ili više sljedećih skupina: amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
R5 i R6 su nezavisno odabrani od sljedećih skupina:
- H,
- alkil (C1-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- alkilen (C2-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- alkin (C2-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- cikloalkil (C3-C8), supstituiran ili ne, s alkil amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- heterocikloalkil (C3-C8), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- aril (C6-C14), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- heteroaril (C1-C13), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- aril (C6-C14) alkil (C1-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
R5 i R6 mogu formirati, zajedno s atomom ugljika za koji su vezani, prsten od m članova (m je između 3 i 8), koji sadrži ili ne sadrži jedan ili više heteroatoma odabranih od N, O, S, i može biti supstituiran s jednom ili više sljedećih skupina: amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
ili može formirati, s atomom ugljika policiklički ostatak C10-C30, supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
dušikov atom heterocikloalkilne skupine ili heteroarila može biti supstituiran sa skupinom alkil (C1-C5), cikloalkil (C3-C8), aril (C6-C14), aril (C6-C14) alkil (C1-C5) ili acil (C1-C6),
s izuzetkom spojeva formule I u kojima:
a) R1 = H, R2 = H, R3 = H, R5 = CH3, R6 = CH3 i R4 = fenetil, fenoksietil, 2-feniltioizopropil ili benzil;
b) R1 = H, R2 = H, R3 = H ili CH3, R4 = H, metil, butil ili fenetil, R5 = H ili etil i R6 je 3-metil-5-izoksazolil, 5-metil-3-izoksazolil, 3-metil-5-pirazolil ili (5-metil-3-izoksazolil)metil,
c) R1, R2, R3 i R4 predstavljaju atom vodika,
kao i tautomerni, enantiomerni, dijastereoizomerni i epimerni oblici i farmaceutski prihvatljive soli.
Za prsten od m članova formiran od R5 i R6, naročito je poželjan zasićeni prsten, kao npr. skupina cikloheksil, piperidinil ili tetrahidropiranil.
Za policikličku skupinu formiranu od R5 i R6, naročito je poželjna policiklička ugljična skupina, eventualno supstituirana, i naročito steroidni ostatak.
Naročito poželjna skupina spojeva formule (I) je ona, u kojoj R5 je vodik.
Još jedna poželjna skupina spojeva formule (I) je ona, u kojoj R5 i R6 formiraju, zajedno s ugljikovim atomom za koji su vezani, prsten od m članova (m je između 3 i 8), koji sadrži ili ne sadrži jedan ili više heteroatoma odabranih od N, O, S, i može biti supstituiran s jednom ili više od sljedećih skupina: alkil (C1-C5), amino, hidroksi, alkilamino (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), aril (C6-C14), aril (C6-C14)-alkoksi (C1-C5),
ili formiraju s ugljikovim atomom policiklički ostatak od C10-C30 atoma, supstituiran ili ne, s amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil.
Još jedna poželjna skupina spojeva formule (I) je ona, u kojoj R5 i R6 su nezavisno odabrani iz sljedeće skupine:
- alkil (C1-C20), supstituiran ili ne, s amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil.
Jedna naročito poželjna skupina spojeva formule (I) je ona, u kojoj R1 i R2 su nezavisno odabrani iz ranije navedenih skupina, osim atoma vodika, i R3 i R4 su vodik. Još naročitije, poželjna skupina spojeva formule (I) je ona, u kojoj R1 i R2 su alkil skupina, poželjno metil, i R3 i R4 su vodik.
Izum se jednako odnosi na tautomerne oblike, enantiomere, dijastereomere i epimere spojeva opće formule (I).
Spojevi opće formule (I) imaju bazične atome dušika, koji mogu stvarati monosoli ili disoli s organskim ili mineralnim kiselinama.
Spojevi opće formule (I) se mogu pripraviti reakcijom spoja opće formule (II)
[image]
u kojoj R1, R2, R3 i R4 su kako je definirano ranije, sa spojem opće formule (III), (IV) ili (V)
[image]
u kojima R5 i R6 su kako je definirano ranije i R7 je skupina metil ili etil, u polarnom otapalu (na primjer etanolu ili dimetilformamidu), u prisutnosti organske (na primjer kamforsulfonske kiseline) ili mineralne kiseline (na primjer kloridne kiseline).
Spojevi opće formule (II) su bigvanidi, čija sinteza je poznata stručnjacima. Citiramo, na primjer, određene objave koje opisuju sintezu tih spojeva (FR 1537604, FR 2132396; K. H. Slotta i R. Tschesche, Ber., 1929(62b), 1398; S. L. Shapiro, V. A. Parino, E. Rogow i L. Freedman, J. Org. Chem., 1959(81), 3725; S. L. Shapiro, V. A. Parino, i L. Freedman, J. Org. Chem., 1959(81), 3728; S. L. Shapiro, V. A. Parino, i L. Freedman, J. Org. Chem., 1959(81), 4636).
Spojevi iz ovog izuma se upotrebljavaju za liječenje bolesti povezanih sa sindromom rezistencije na inzulin (sindrom X). Rezistencija na inzulin je karakterizirana smanjenjem djelovanja inzulina (usp. Presse Médicale, 1997, 26 (br. 14), 671-677) i upletena je u znatan broj patoloških stanja, kao što su dijabetes, i određenije dijabetes neovisan o inzulinu (dijabetes tipa II ili NIDDM), dislipidemija, pretilost, arterijska hipertenzija, kao i određene mikrovaskularne i markovaskularne komplikacije kao npr. ateroskleroza, retinopatije i neuropatije.
O toj temi, poziva se, na primjer, na Diabetes, vol. 37, 1988, 1595-1607; Journal of Diabetes and its complications, 1998, 12, 110-119 ili Horm. Res., 1992, 38, 28-32).
Naime, spojevi iz izuma pokazuju pojačano hipoglikemijsko djelovanje.
Spojevi prema ovom izumu se jednako upotrebljavaju za tretiranje kroničnih komplikacija, koje nastaju zbog stvaranja "krajnjih produkata napredne glikozilacije" ("advanced glycosylation end-products"), označenih AGE, rezultat reakcije glikoksidacije između glukoze, njenih derivata oksidacije i amino funkcionalnih skupina proteina, koje reakcije spominje Maillard, na primjer glikozilacija glioksala.
Zapravo, nedavni podaci iz literature jasno ukazuju na ulogu AGE na bubrežne komplikacije (Nephr. Dial. Transplant., 2000, 15 (supl. 2), 7-11), na aterosklerozu, Alzheimerovu bolest i druge neurodegenerativne bolesti (Glycoconj. J., 1998, 15(10), 1039-42; Brain Res., 2001, 888(2), 256). Formiranje AGE isto tako može imati važnu ulogu u patogenezi angiopatije, naročito kod dijabetičara, kao i kod senilnosti (J. Neuropathol. Exp. Neurol., 2000, 59(12), 1094).
Cilj sadašnjeg izuma su jednako tako farmaceutski pripravci koji sadržavaju, kao aktivnu tvar, spoj prema izumu.
Ovi farmaceutski pripravci su naročito namijenjeni za liječenje dijabetesa, patologija nastalih zbog formiranja AGE, kao što su, na primjer, bubrežne komplikacije, ateroskleroza, angiopatija, Alzheimerova bolest, neurodegenerativne bolesti i senilnost.
Farmaceutski pripravci prema izumu mogu biti predstavljeni u oblicima poželjnim za primjenu parenteralnim, oralnim, rektalnim, permukoznim ili perkutanim putem.
Oni su također predstavljeni u obliku injekcijskih otopina ili suspenzija ili više-dozirnih bočica, u obliku tableta ili obloženih tableta, dražeja, kapsula, mekih želatinskih kapsula, pilula, vrećica, prašaka, supozitorija ili rektalnih kapsula, otopina ili suspenzija, za perkutanu upotrebu u polarnom otapalu, za permukoznu upotrebu.
Odgovarajuće pomoćne tvari za takve primjene su derivati celuloze, ili mikrokristalne celuloze, karbonati zemnoalkalijskih metala, magnezij fosfat, škrobovi, modificirani škrobovi, laktoza, za čvrste oblike.
Za rektalnu upotrebu, kakao maslac ili stearati polietilenglikola su poželjni ekscipijenti.
Za parenteralnu upotrebu, nosači koji se najčešće upotrebljavaju su voda, vodene otopine, fiziološka otopina, izotonične otopine..
Doziranje može varirati unutar određenih granica (0,5 mg do 1000 mg), što ovisi o terapijskoj indikaciji i putu primjene, kao i dobi i masi subjekta.
Kao primjer, prikazano je nekoliko bigvanida formule II koji se upotrebljavaju za sintezu derivata formule I.
TABLICA I
[image]
Sljedeći primjeri ilustriraju dobivanje spojeva formule I.
PRIMJER I
Sinteza 2-amino-3,6-dihidro-4-dimetilamino-6-etil-1,3,5-triazin klorhidrata
U otopinu spoja A (25,7 g; 0,155 mol) u 200 mL DMF se doda 23 mL propionaldehida i 3,6 g kamforsulfonske kiseline. Nakon 2 sata refluksiranja, otapalo se ukloni pod vakuumom i doda se 100 mL acetonitrila. Krutina se ocijedi i osuši (21,9 g; 69%).
Talište = 218-220 ºC
NMR 1H (DMSO-d6, 200 MHz): 1,10 (t, 3H); 1,80 (m, 2H); 3,20 (s, 6H); 4,83 (m, 1H); 7,57 (m, 2H); 8,65 (s, 1H); 8,90 (s, 1H)
NMR 13C (DMSO-d6, 50 MHz): 6,41 (CH3); 27,59 (CH3); 35,64 (CH3); 60,75 (CH); 155,01 (C=N); 156,67 (C=N)
PRIMJER 2
Sinteza 2,4-bis-dimetilamino-3,6-dihidro-6-metil-1,3,5-triazin klorhidrata
Otopini spoja E (41,10 g, 0,212 mol) u 200 ml apsolutnog etanola se doda 61 mL acetala i 5 g kamforsulfonske kiseline. Sve se refluksira 72 sata, zatim koncentrira. Ostatak se triturira s acetonitrilom i krutina se ocijedi, zatim prekristalizira iz acetonitrila. Dobiveno je 24 g (51,5%) krutine.
talište = 200-202 ºC
NMR 1H (DMSO-d6, 200 MHz): 1,34 (d, 3H); 3,02 (s, 6H); 4,72 (m, 1H); 4,83 (m, 1H); 8,80 (s, 2H)
NMR 13C (DMSO-d6, 50 MHz): 22,59 (CH3); 37,76 (CH3); 59,02 (CH); 156,35 (C=N)
Karakteristike tih spojeva i ostalih spojeva formule I su prikazane u tablici II, niže:
TABLICA II
[image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
Dalje u tekstu će biti prikazani rezultati farmakoloških studija.
STUDIJA ANTIDIJABETIČKOG DJELOVANJA KOD ŠTAKORA N0STZ
Antidijabetičko djelovanje spojeva formule (I) oralnim putem, je određeno na eksperimentalnom modelu dijabetesa neovisnog inzulinu induciranom kod štakora pomoću Streptozotocina.
Model dijabetesa, neovisnog o inzulinu, je postignut kod štakora jednom neonatalnom injekcijom (na dan rođenja) streptozotocina.
Upotrebljavani dijabetički štakori su bili stari 8 tjedana. Izvršeno je prilagođivanje životinja, od dana njihovog rođenja do dana pokusa, u živinarniku s reguliranom temperaturom od 21 do 22 ºC i podvrgavanjem fiksnom ciklusu svjetla (od 7 do 19 h) i tame (od 19 do 7 h). Njihovo održavanje se sastojalo od režima hranjenja, voda i hrana su bili pruženi "ad libitum", osim posta 2 sata prije testova, kad je hrana oduzeta (postapsorpcijska faza).
Štakori su bili tretirani oralnim putem tijekom jednog (J1) ili četiri (J4) dana s ispitivanim produktom. Dva sata nakon zadnje primjene produkta i 30 minuta nakon anestezije životinja pentobarbital natrijem (Nembutal????), uzet je uzorak krvi od 300 µL iz repa.
Kao primjer, u tablici III su prikazani dobiveni rezultati. Ovi rezultati pokazuju djelotvornost spojeva formule (I) za smanjivanje glikemije kod dijabetičkih životinja. Ovi rezultati su izraženi kao postotak razvoja glikemije na J1 i J4 (broj dana tretiranja), u usporedbi sa J0 (prije tretiranja).
TABLICA III
[image] [image]
STUDIJA ANTIGLIKEMIJSKOG DJELOVANJA
Spojevi (I) su također sposobni inhibirati reakcije koje Maillard naziva "efektom hvatanja" na α-dikarbonilnim derivatima kao što je glioksal – to je antiglikemijski efekt. Ovaj inhibitorski efekt, spojeva iz izuma, na Maillardovu reakciju, je proučen in vitro određivanjem ketamina ("fruktozamina") proizvedenih tijekom inkubacije albumina s metilglioksalom u prisutnosti ili bez spoja (I) prema izumu.
Otopina goveđeg albumina koncentracije 6,6 mg/ml u fosfatnom puferu 0,2 M pH 7,4, je inkubirana s metilglioksalom 1 mM u prisutnosti ili bez spoja prema izumu u koncentraciji od 10 mM. Inkubacija je izvedena u sterilnim uvjetima pri 37 ºC tijekom 6 dana. Na kraju perioda inkubacije, izmjerena je količina ketamina pomoću kompleta za određivanje fruktozamina, koji je komercijalno dostupan (komplet "FRA", referenca proizvoda: 0757055, proizvodi Roche S.A.) prema uputama proizvođača.
Kao primjer, u tablici IV su prikazani dobiveni rezultati u ovim eksperimentalnim uvjetima: postotak fruktozamina nakon inkubacije albumina s metilglioksalom u prisutnosti spojeva (I) prema izumu, u usporedbi s postotkom fruktozamina kad je albumin inkubiran s metilglioksalom u odsutnosti spojeva (I) prema izumu.
TABLICA IV
[image]
Claims (13)
1. Spojevi, naznačeni time, što imaju opću formulu (I)
[image]
u kojoj:
R1, R2, R3 i R4 su nezavisno odabrani od sljedećih skupina:
- H,
- alkil (C1-C20), supstituiran ili ne, s halogenom, alkil (C1-C5), alkoksi (C1-C5), cikloalkil (C3-C8),
- alkilen (C2-C20), supstituiran ili ne, s halogenom, alkil (C1-C5), alkoksi (C1-C5)
- alkin (C2-C20), supstituiran ili ne, s halogenom, alkil (C1-C5), alkoksi (C1-C5)
- cikloalkil (C3-C8), supstituiran ili ne, s alkil (C1-C5), alkoksi (C1-C5)
- heterocikloalkil (C3-C8), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s alkil (C1-C5), alkoksi (C1-C5)
- aril (C6-C14) alkil (C1-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil
- aril (C6-C14), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- heteroaril (C1-C13), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
R1 i R2 iz jednog dijela i R3 i R4 iz drugog dijela mogu s atomom dušika formirati prsten od n članova (n je između 3 i 8), koji sadrži ili ne sadrži jedan ili više heteroatoma odabranih od N, O, S, i može biti supstituiran s jednom ili više sljedećih skupina: amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
R5 i R6 su nezavisno odabrani od sljedećih skupina:
- H,
- alkil (C1-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- alkilen (C2-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- alkin (C2-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- cikloalkil (C3-C8), supstituiran ili ne, s alkil amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- heterocikloalkil (C3-C8), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- aril (C6-C14), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- heteroaril (C1-C13), koji ima više heteroatoma odabranih od N, O, S, i supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
- aril (C6-C14) alkil (C1-C20), supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
R5 i R6 mogu formirati, zajedno s atomom ugljika za koji su vezani, prsten od m članova (m je između 3 i 8), koji sadrži ili ne sadrži jedan ili više heteroatoma odabranih od N, O, S, i može biti supstituiran s jednom ili više sljedećih skupina: amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
ili može formirati, s atomom ugljika, policiklički ostatak C10-C30, supstituiran ili ne, s amino, hidroksi, tio, halogenom, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
dušikov atom heterocikloalkilne skupine ili heteroarila može biti supstituiran sa skupinom alkil (C1-C5), cikloalkil (C3-C8), aril (C6-C14), aril (C6-C14) alkil (C1-C5) ili acil (C1-C6),
s izuzetkom spojeva formule I u kojima:
a) R1 = H, R2 = H, R3 = H, R5 = CH3, R6 = CH3 i R4 = fenetil, fenoksietil, 2-feniltioizopropil ili benzil;
b) R1 = H, R2 = H, R3 = H ili CH3, R4 = H, metil, butil ili fenetil, R5 = H ili etil i R6 je 3-metil-5-izoksazolil, 5-metil-3-izoksazolil, 3-metil-5-pirazolil ili (5-metil-3-izoksazolil)metil,
c) R1, R2, R3 i R4 predstavljaju atom vodika,
kao i njihovi tautomerni, enantiomerni, dijastereoizomerni i epimerni oblici i farmaceutski prihvatljive soli.
2. Spojevi formule (I) prema zahtjevu 1, naznačeni time, što R5 je vodik.
3. Spojevi formule (I) prema zahtjevu 1, naznačeni time, što R5 i R6 formiraju, zajedno s ugljikovim atomom za koji su vezani, prsten od m članova (m je između 3 i 8), koji sadrži ili ne sadrži jedan ili više heteroatoma odabranih od N, O, S, i može biti supstituiran s amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil,
ili formiraju s ugljikovim atomom policiklički ostatak od C10-C30 atoma, supstituiran ili ne, s amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil.
4. Spojevi formule (I) prema zahtjevu 1, naznačeni time, što R5 je alkilna skupina (C2-C20), supstituirana ili ne, s amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil.
5. Spoj formule (I) prema zahtjevu 1, naznačen time, što R5 i R6 su odabrani od alkilnih skupina (C1-C20), supstituiranih ili ne, s amino, hidroksi, tio, halogen, alkil (C1-C5), alkoksi (C1-C5), alkiltio (C1-C5), alkilamino (C1-C5), aril (C6-C14) oksi, aril (C6-C14) alkoksi (C1-C5), cijano, trifluormetil, karboksi, karboksimetil ili karboksietil.
6. Spojevi formule (I) prema bilo kojem od zahtjeva 1 do 5, naznačeni time, što R1 i R2 su nezavisno odabrani od skupina navedenih u zahtjevu 1, osim atoma vodika i R3 i R4 predstavljaju vodik.
7. Spojevi formule (I) prema zahtjevu 6, naznačeni time, što R1 i R2 su metilna skupina i R3 i R4 su vodik.
8. Postupak dobivanja spoja prema zahtjevu 1, naznačen time, što sadrži reakciju spoja opće formule (II)
[image]
u kojoj R1, R2, R3 i R4 su kako je definirano ranije, sa spojem opće formule (III), (IV) ili (V)
[image]
u kojima R5 i R6 su kako je definirano ranije, i R7 je skupina metil ili etil, u polarnom otapalu u prisutnosti organske ili mineralne kiseline.
9. Farmaceutski pripravak, naznačen time, što kao aktivnu tvar sadrži spoj prema bilo kojem od zahtjeva 1 do 7.
10. Upotreba spoja prema bilo kojem od zahtjeva 1 do 7, naznačena time, što se upotrebljava za proizvodnju lijeka namijenjenog za tretiranje patologija povezanih sa sindromom rezistencije na inzulin.
11. Upotreba spoja prema bilo kojem od zahtjeva 1 do 7, naznačena time, što se upotrebljava za proizvodnju lijeka namijenjenog za tretiranje dijabetesa.
12. Upotreba spoja prema bilo kojem od zahtjeva 1 do 7, naznačena time, što se upotrebljava za proizvodnju lijeka namijenjenog za tretiranje patologija nastalih zbog stvaranja AGE.
13. Upotreba spoja prema bilo kojem od zahtjeva 1 do 7, naznačena time, što se upotrebljava za proizvodnju lijeka namijenjenog za tretiranje patologija odabranih od bubrežnih komplikacija, ateroskleroze, angiopatije, Alzheimerove bolesti, neurodegenerativnih bolesti i senilnosti.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0000996A FR2804113B1 (fr) | 2000-01-26 | 2000-01-26 | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20020625A2 true HRP20020625A2 (en) | 2003-10-31 |
Family
ID=8846333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20020625A HRP20020625A2 (en) | 2000-01-26 | 2002-07-24 | Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
Country Status (37)
Country | Link |
---|---|
US (4) | US7034021B2 (hr) |
EP (1) | EP1250328B2 (hr) |
JP (1) | JP4926357B2 (hr) |
KR (1) | KR100722438B1 (hr) |
CN (1) | CN1195743C (hr) |
AP (1) | AP2002002578A0 (hr) |
AR (1) | AR027293A1 (hr) |
AT (1) | ATE332294T1 (hr) |
AU (1) | AU782307B2 (hr) |
BG (1) | BG106933A (hr) |
BR (1) | BRPI0107815B8 (hr) |
CA (1) | CA2397636C (hr) |
CY (1) | CY1105344T1 (hr) |
CZ (1) | CZ303445B6 (hr) |
DE (1) | DE60121294T3 (hr) |
DK (1) | DK1250328T4 (hr) |
EA (1) | EA005378B1 (hr) |
EE (1) | EE05003B1 (hr) |
ES (1) | ES2267715T5 (hr) |
FR (1) | FR2804113B1 (hr) |
HK (1) | HK1050529A1 (hr) |
HR (1) | HRP20020625A2 (hr) |
HU (1) | HU230790B1 (hr) |
IL (1) | IL150530A0 (hr) |
IS (1) | IS6467A (hr) |
MA (1) | MA25650A1 (hr) |
MX (1) | MXPA02007232A (hr) |
NO (1) | NO20023532L (hr) |
OA (1) | OA12165A (hr) |
PL (1) | PL205345B1 (hr) |
PT (1) | PT1250328E (hr) |
SI (1) | SI1250328T2 (hr) |
SK (1) | SK287647B6 (hr) |
TN (1) | TNSN01012A1 (hr) |
WO (1) | WO2001055122A1 (hr) |
YU (1) | YU55602A (hr) |
ZA (1) | ZA200205314B (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
WO2004054989A1 (ja) | 2002-12-17 | 2004-07-01 | Hamari Chemicals, Ltd. | 新規2,4−ジアミノ−1,3,5−トリアジン誘導体 |
FR2853650B1 (fr) * | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
KR20080015861A (ko) * | 2005-06-14 | 2008-02-20 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제로서의 화합물의 제조방법 및용도 |
FR2896158B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase. |
FR2896161B1 (fr) | 2006-01-13 | 2008-04-04 | Merck Sante Soc Par Actions Si | Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique. |
FR2896160B1 (fr) * | 2006-01-13 | 2008-04-25 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agonistes du ppar alpha. |
FR2896159B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
DE102007054416A1 (de) * | 2007-11-13 | 2009-05-14 | Studiengesellschaft Kohle Mbh | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind |
DE102008007314A1 (de) * | 2008-02-02 | 2009-08-06 | Merck Patent Gmbh | Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten |
JP5411929B2 (ja) * | 2008-05-20 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | マンノシルトランスフェラーゼ阻害剤を使用した異種蛋白質の効率的生産 |
EA018921B1 (ru) * | 2008-05-23 | 2013-11-29 | Поксел Сас | Способ синтеза производных 3,6-дигидро-1,3,5-триазина |
JPWO2010024225A1 (ja) * | 2008-08-25 | 2012-01-26 | 浜理薬品工業株式会社 | 新規ジヒドロトリアジン誘導体 |
EP2355829B1 (en) | 2008-12-12 | 2014-12-31 | Poxel S.A.S. | Combination of insulin with triazine derivatives and its use for treating diabetes |
EP2367802B1 (en) | 2008-12-12 | 2016-04-20 | Poxel | Tetrahydrotriazine compounds for treating diseases associated with ampk activity |
WO2010103040A1 (en) | 2009-03-10 | 2010-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension |
US8742102B2 (en) | 2009-03-26 | 2014-06-03 | Poxel | Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization |
FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
FR2948026B1 (fr) | 2009-07-17 | 2011-12-02 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine |
FR2948028B1 (fr) | 2009-07-17 | 2011-12-02 | Merck Sante Sas | Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine |
WO2011154496A1 (en) | 2010-06-09 | 2011-12-15 | Poxel | Treatment of type 1 diabetes |
TWI436768B (zh) | 2010-06-09 | 2014-05-11 | Poxel | 第2型糖尿病之治療 |
SI2646422T1 (sl) | 2010-12-01 | 2016-02-29 | Poxel | Ločevanje enantiomerov derivatov triazina z uporabo vinske kisline |
RU2658819C2 (ru) * | 2016-05-26 | 2018-06-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет" | Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью |
FR3068601B1 (fr) | 2017-07-05 | 2021-02-19 | Eric Joseph Marie Fulgence Janin | Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire |
EP3691650A1 (en) | 2017-10-02 | 2020-08-12 | Poxel | Methods of treating heart failure with preserved ejection fraction |
EP3801542B1 (en) | 2018-06-06 | 2022-08-10 | Poxel SA | Methods of treating subjects having diabetes with chronic kidney disease |
WO2019238647A1 (en) | 2018-06-14 | 2019-12-19 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
WO2022152138A1 (zh) * | 2021-01-15 | 2022-07-21 | 中国医药研究开发中心有限公司 | 稠和杂环类化合物及其制备方法和医药用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3287366A (en) * | 1963-12-24 | 1966-11-22 | American Cyanamid Co | Novel 1, 2-dihydro-s-triazines |
US3286366A (en) * | 1964-10-26 | 1966-11-22 | Seligman Monroe | Apparatus for freeze drying products in small containers |
JPS4856692A (hr) * | 1971-11-19 | 1973-08-09 | ||
JPS4864088A (hr) * | 1971-12-13 | 1973-09-05 | ||
JPS5414986A (en) * | 1977-07-01 | 1979-02-03 | Taiho Pharmaceutical Co Ltd | Production of dihydrooss triazine derivative |
US4246408A (en) * | 1979-03-08 | 1981-01-20 | Icn Pharmaceuticals | Imidazo[1,2-a]-s-triazine |
GR74944B (hr) * | 1980-07-02 | 1984-07-12 | Merck & Co Inc | |
US4277602A (en) * | 1980-07-02 | 1981-07-07 | Merck & Co., Inc. | 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides |
US4576945A (en) * | 1982-10-26 | 1986-03-18 | Sanders Mark E | Hexaalkylmelamine-amino-oxy compounds |
JPS6141915A (ja) | 1984-08-03 | 1986-02-28 | Omron Tateisi Electronics Co | 測距装置 |
DD257010A1 (de) * | 1987-01-13 | 1988-06-01 | Berlin Chemie Veb | Ergotrope mittel |
DE3801113A1 (de) * | 1987-07-23 | 1989-02-02 | Bayer Ag | Substituierte triazine |
IT1244870B (it) * | 1990-09-11 | 1994-09-12 | Ministero Dall Uni E Della Ric | Composti ammelinici |
DE19641692A1 (de) * | 1996-10-10 | 1998-04-23 | Bayer Ag | Substituierte 2,4-Diamino-1,3,5-triazine |
IL136339A0 (en) * | 1997-12-12 | 2001-05-20 | Abbott Lab | Triazine angiogenesis inhibitors |
FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
-
2000
- 2000-01-26 FR FR0000996A patent/FR2804113B1/fr not_active Expired - Lifetime
-
2001
- 2001-01-24 TN TNTNSN01012A patent/TNSN01012A1/fr unknown
- 2001-01-25 ES ES01907700T patent/ES2267715T5/es not_active Expired - Lifetime
- 2001-01-25 EA EA200200790A patent/EA005378B1/ru not_active IP Right Cessation
- 2001-01-25 KR KR1020027009459A patent/KR100722438B1/ko active IP Right Grant
- 2001-01-25 AP APAP/P/2002/002578A patent/AP2002002578A0/en unknown
- 2001-01-25 PT PT01907700T patent/PT1250328E/pt unknown
- 2001-01-25 SI SI200130600T patent/SI1250328T2/sl unknown
- 2001-01-25 DE DE60121294T patent/DE60121294T3/de not_active Expired - Lifetime
- 2001-01-25 BR BR0107815A patent/BRPI0107815B8/pt not_active IP Right Cessation
- 2001-01-25 US US10/181,223 patent/US7034021B2/en not_active Expired - Lifetime
- 2001-01-25 MX MXPA02007232A patent/MXPA02007232A/es active IP Right Grant
- 2001-01-25 YU YU55602A patent/YU55602A/sh unknown
- 2001-01-25 CZ CZ20022462A patent/CZ303445B6/cs not_active IP Right Cessation
- 2001-01-25 HU HU0204087A patent/HU230790B1/hu unknown
- 2001-01-25 CN CNB018041027A patent/CN1195743C/zh not_active Expired - Lifetime
- 2001-01-25 IL IL15053001A patent/IL150530A0/xx unknown
- 2001-01-25 AU AU35603/01A patent/AU782307B2/en not_active Expired
- 2001-01-25 PL PL357191A patent/PL205345B1/pl unknown
- 2001-01-25 EE EEP200200414A patent/EE05003B1/xx unknown
- 2001-01-25 JP JP2001555064A patent/JP4926357B2/ja not_active Expired - Lifetime
- 2001-01-25 EP EP01907700A patent/EP1250328B2/fr not_active Expired - Lifetime
- 2001-01-25 DK DK01907700.7T patent/DK1250328T4/da active
- 2001-01-25 OA OA1200200225A patent/OA12165A/fr unknown
- 2001-01-25 WO PCT/FR2001/000241 patent/WO2001055122A1/fr active IP Right Grant
- 2001-01-25 AT AT01907700T patent/ATE332294T1/de active
- 2001-01-25 SK SK976-2002A patent/SK287647B6/sk not_active IP Right Cessation
- 2001-01-25 CA CA2397636A patent/CA2397636C/fr not_active Expired - Lifetime
- 2001-01-26 AR ARP010100337A patent/AR027293A1/es active IP Right Grant
-
2002
- 2002-07-03 ZA ZA2002/05314A patent/ZA200205314B/en unknown
- 2002-07-11 IS IS6467A patent/IS6467A/is unknown
- 2002-07-17 BG BG106933A patent/BG106933A/xx unknown
- 2002-07-22 MA MA26737A patent/MA25650A1/fr unknown
- 2002-07-24 NO NO20023532A patent/NO20023532L/no not_active Application Discontinuation
- 2002-07-24 HR HR20020625A patent/HRP20020625A2/hr not_active Application Discontinuation
-
2003
- 2003-04-11 HK HK03102653A patent/HK1050529A1/xx not_active IP Right Cessation
-
2005
- 2005-03-22 US US11/085,145 patent/US7452883B2/en not_active Expired - Lifetime
-
2006
- 2006-09-08 CY CY20061101287T patent/CY1105344T1/el unknown
-
2007
- 2007-10-30 US US11/976,936 patent/US7767676B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/979,140 patent/US20080108591A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020625A2 (en) | Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses | |
US3780040A (en) | 2-substituted-3,4-dihydroquinazolines | |
CA1219582A (en) | Pharmaceutical compositions capable of increasing cerebral serotonin concentration | |
DK169818B1 (da) | Ergolinderivater, fremgangsmåde til fremstilling deraf, samt farmaceutisk præparat indeholdende disse | |
ES2207325T3 (es) | ((aminoiminomethil) amino) alcanocarboxamidas y sus aplicaciones terapeuticas. | |
US4338319A (en) | Method for the treatment of chronic obstructive airway or cardiac diseases | |
JP2798628B2 (ja) | 癲癇治療用の5−アミノカルボニル−5H−ジベンゾ[a,d]シクロヘプテン−5,10−イミン | |
PL92078B1 (hr) | ||
JP6595011B2 (ja) | 新規ホスホジエステラーゼ5阻害剤とその使用 | |
Reisner et al. | Synthesis and hypoglycemic activity of 2-(. omega.-substituted alkylamino)-2-imidazolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20030124 Year of fee payment: 2 |
|
A1OB | Publication of a patent application | ||
OBST | Application withdrawn |